H.C. Wainwright adjusted its outlook on Zentalis Pharmaceuticals (NASDAQ:ZNTL), reducing the price target to $10.00 from the previous $20.00, yet reaffirming a Buy rating on the company's shares. The ...
Some results have been hidden because they may be inaccessible to you